Cardalis

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

benazepril hydrochloride, spironolactone

Available from:

Ceva Santé Animale

ATC code:

QC09BA07

INN (International Name):

benazepril hydrochloride, spironolactone

Therapeutic group:

psi

Therapeutic area:

KARDIOVASKULARNOG SUSTAVA

Therapeutic indications:

Za liječenje kongestivnog zatajenja srca uzrokovanog kroničnom degenerativnom bolesti pilula kod pasa (s prikladnom diuretskom podrškom).

Product summary:

Revision: 4

Authorization status:

odobren

Authorization date:

2012-07-23

Patient Information leaflet

                                17
B. UPUTA O VMP
18
UPUTA O VMP
Cardalis 2,5 mg/20 mg tablete za žvakanje za pse
Cardalis 5 mg/40 mg tablete za žvakanje za pse
Cardalis 10 mg/80 mg tablete za žvakanje za pse
1.
IME I ADRESA NOSITELJA ODOBRENJA ZA STAVLJANJE U PROMET I
NOSITELJA ODOBRENJA ZA PROIZVODNJU ODGOVORNOG ZA PUŠTANJE
PROIZVODNE SERIJE, AKO JE RAZLIČITO
Nositelj odobrenja za stavljanje u promet:
Ceva Santé Animale
10 av. de La Ballastiere
33500 Libourne
Francuska
Nositelj odobrenja za proizvodnju za puštanje proizvodne serije:
Ceva Santé Animale
Z.I. Tres le Bois
22600 Loudeac
Francuska
Catalent Germany Schorndorf GmbH
Steinbeisstrasse 2
73614 Schorndorf
Njemačka
2.
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA
Cardalis 2,5 mg/20 mg tablete za žvakanje za pse
benazepril HCl 2,5 mg, spironolakton 20 mg
Cardalis 5 mg/40 mg tablete za žvakanje za pse
benazepril HCl 5 mg, spironolakton 40 mg
Cardalis 10 mg/80 mg tablete za žvakanje za pse
benazepril HCl 10 mg, spironolakton 80 mg
3.
NAVOĐENJE DJELATNE(IH) TVARI I DRUGIH SASTOJAKA
_ _
JEDNA TABLETA ZA ŽVAKANJE SADRŽI:
BENAZEPRIL HIDROKLORID
(HCL)
(benazeprilum HCl)
SPIRONOLAKTON
(spironolactonum)
Cardalis 2,5 mg/20 mg tablete
2,5 mg
20 mg
Cardalis 5 mg/40 mg tablete
5 mg
40 mg
Cardalis 10 mg/80 mg tablete
10 mg
80 mg
Tablete su smeđe boje, s umjetnim okusom, duguljastog oblika s
razdjelnom linijom i namijenjene
žvakanju.
19
4.
INDIKACIJE
Za liječenje kongestivnog zatajenja srca uzrokovanog kroničnom
degenerativnom bolesti zalistaka u
pasa (prema potrebi s diuretskom potporom)._ _
5.
KONTRAINDIKACIJE
Ne primjenjivati tijekom graviditeta i laktacije (vidjeti dio
„Graviditet i laktacija“).
Ne primjenjivati u pasa koji su namijenjeni za razmnožavanje.
Ne primjenjivati u pasa koji pate od hipoadrenokorticizma,
hiperkalijemije ili hiponatrijemije.
Ne primjenjivati u kombinaciji s nesteroidnim protuupalnim lijekovima
(NSAIDs) psima s oštećenom
funkcijom bubrega.
Ne primjenjivati u slučaju preosjetljivosti na inhibitore angiotenzin
konvertirajućeg enzima (ACE
inhibitori) ili n
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
DODATAK I
SAŽETAK OPISA SVOJSTAVA
2
1.
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA
Cardalis 2,5 mg/20 mg tablete za žvakanje za pse
Cardalis 5 mg/40 mg tablete za žvakanje za pse
Cardalis 10 mg/80 mg tablete za žvakanje za pse
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Jedna tableta za žvakanje sadrži:
DJELATNE TVARI:
BENAZEPRIL
HIDROKLORID (HCL)
(benazeprilum HCl)
SPIRONOLAKTON
(spironolactonum)
Cardalis 2,5 mg/20 mg tablete
2,5 mg
20 mg
Cardalis 5 mg/40 mg tablete
5 mg
40 mg
Cardalis 10 mg/80 mg tablete
10 mg
80 mg
POMOĆNE TVARI:
Potpuni popis pomoćnih tvari vidi u odjeljku 6.1.
3.
FARMACEUTSKI OBLIK
Tableta za žvakanje.
Smeđe, duguljaste tablete za žvakanje umjetnim okusom s jednom
razdjelnom crtom.
Tablete se mogu podijeliti na dvije jednake polovice.
4.
KLINIČKE POJEDINOSTI
4.1
CILJNE VRSTA ŽIVOTINJA
Psi.
4.2
INDIKACIJE ZA PRIMJENU, NAVESTI CILJNE VRSTE ŽIVOTINJA
Za liječenje kongestivnog zatajenja srca uzrokovanog kroničnom
degenerativnom bolesti zalistaka u
pasa (prema potrebi s diuretskom potporom).
4.3
KONTRAINDIKACIJE
Ne primjenjivati tijekom graviditeta i laktacije (vidjeti dio 4.7).
Ne primjenjivati u pasa koji su namijenjeni za razmnožavanje.
Ne primjenjivati u pasa koji pate od hipoadrenokorticizma,
hiperkalijemije ili hiponatrijemije.
Ne primjenjivati u kombinaciji s nesteroidnim protuupalnim lijekovima
(NSAIDs), psima s oštećenom
funkcijom bubrega.
Ne primjenjivati u slučaju preosjetljivosti na inhibitore angiotenzin
konvertirajućeg enzima (ACE
inhibitori) ili na bilo koju pomoćnu tvar.
Ne primjenjivati u slučajevima zatajenja istisne funkcije srca
uzrokovanog stenozom aorte ili plućne
arterije.
3
4.4
POSEBNA UPOZORENJA ZA SVAKU OD CILJNIH VRSTA ŽIVOTINJA
Nema.
4.5
POSEBNE MJERE OPREZA PRILIKOM PRIMJENE
Posebne mjere opreza prilikom primjene na životinjama
Prije početka liječenja benazeprilom i spironolaktonom treba
procijeniti serumske razine kalija,
posebice u pasa koji mogu patiti od hipoadrenokorticizma,
hiperkalijemije ili hiponatrijemije. Za
razliku od ljudi, povećana
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 04-11-2021
Summary of Product characteristics Summary of Product characteristics Bulgarian 04-11-2021
Public Assessment Report Public Assessment Report Bulgarian 17-06-2013
Patient Information leaflet Patient Information leaflet Spanish 04-11-2021
Public Assessment Report Public Assessment Report Spanish 17-06-2013
Patient Information leaflet Patient Information leaflet Czech 04-11-2021
Public Assessment Report Public Assessment Report Czech 17-06-2013
Patient Information leaflet Patient Information leaflet Danish 04-11-2021
Public Assessment Report Public Assessment Report Danish 17-06-2013
Patient Information leaflet Patient Information leaflet German 04-11-2021
Public Assessment Report Public Assessment Report German 17-06-2013
Patient Information leaflet Patient Information leaflet Estonian 04-11-2021
Public Assessment Report Public Assessment Report Estonian 17-06-2013
Patient Information leaflet Patient Information leaflet Greek 04-11-2021
Public Assessment Report Public Assessment Report Greek 17-06-2013
Patient Information leaflet Patient Information leaflet English 04-11-2021
Public Assessment Report Public Assessment Report English 17-06-2013
Patient Information leaflet Patient Information leaflet French 04-11-2021
Public Assessment Report Public Assessment Report French 17-06-2013
Patient Information leaflet Patient Information leaflet Italian 04-11-2021
Public Assessment Report Public Assessment Report Italian 17-06-2013
Patient Information leaflet Patient Information leaflet Latvian 04-11-2021
Public Assessment Report Public Assessment Report Latvian 17-06-2013
Patient Information leaflet Patient Information leaflet Lithuanian 04-11-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 04-11-2021
Public Assessment Report Public Assessment Report Lithuanian 17-06-2013
Patient Information leaflet Patient Information leaflet Hungarian 04-11-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 04-11-2021
Public Assessment Report Public Assessment Report Hungarian 17-06-2013
Patient Information leaflet Patient Information leaflet Maltese 04-11-2021
Public Assessment Report Public Assessment Report Maltese 17-06-2013
Patient Information leaflet Patient Information leaflet Dutch 04-11-2021
Public Assessment Report Public Assessment Report Dutch 17-06-2013
Patient Information leaflet Patient Information leaflet Polish 04-11-2021
Public Assessment Report Public Assessment Report Polish 17-06-2013
Patient Information leaflet Patient Information leaflet Portuguese 04-11-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 04-11-2021
Public Assessment Report Public Assessment Report Portuguese 17-06-2013
Patient Information leaflet Patient Information leaflet Romanian 04-11-2021
Public Assessment Report Public Assessment Report Romanian 17-06-2013
Patient Information leaflet Patient Information leaflet Slovak 04-11-2021
Public Assessment Report Public Assessment Report Slovak 17-06-2013
Patient Information leaflet Patient Information leaflet Slovenian 04-11-2021
Summary of Product characteristics Summary of Product characteristics Slovenian 04-11-2021
Public Assessment Report Public Assessment Report Slovenian 17-06-2013
Patient Information leaflet Patient Information leaflet Finnish 04-11-2021
Public Assessment Report Public Assessment Report Finnish 17-06-2013
Patient Information leaflet Patient Information leaflet Swedish 04-11-2021
Public Assessment Report Public Assessment Report Swedish 17-06-2013
Patient Information leaflet Patient Information leaflet Norwegian 04-11-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 04-11-2021
Patient Information leaflet Patient Information leaflet Icelandic 04-11-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 04-11-2021

View documents history